Overview

DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures

Status:
Not yet recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This is a prospective, comparative, open-label, single-center, randomized, investigator-sponsored clinical study and seeks to investigate clinical outcomes with standard of care and high dose DEXTENZA treatment compared to standard of care topical dexamethasone in patients undergoing trabeculectomy, trabeculectomy Ex-PRESS, Xen Gel stent, and Ahmed Valve surgery. Patients will be followed through 6 months. After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, eyes of n=30 patients will be randomized to one of the following two groups (n=15per group) and followed from Baseline through Month 6.

Phase:

Phase 4

Details

Lead Sponsor:

Brian Jerkins, MD

Collaborator:

Ocular Therapeutix, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate